Cover Image

STUDY OF SERUM LEVELS OF CALCIUM, PHOSPHORUS AND ALKALINE PHOSPHATASE IN CHRONIC KIDNEY DISEASE

FREETHI R

Abstract


BACKGROUND Chronic kidney disease (CKD) is a worldwide public health problem, with increasing prevalence and lethal adverse outcomes like progressive loss of kidney function, cardiovascular disease and premature death. Disturbances in mineral metabolism and bone disease are common complications of CKD and an important cause of morbidity and decreased quality of life in patients with CKD. Patients with renal failure have an increased risk of cardiovascular mortality that may be due in part to vascular calcification. AIMS AND OBJECTIVE To measure serum levels of calcium, phosphorus and alkaline phosphatase in patients in various stages of CKD and to correlate the same with creatinine and estimated Glomerular Filtration Rate (eGFR) values. MATERIALS AND METHODS This is a cross sectional study done at Thanjavur Medical College Hospital. 60 CKD patients and 50 healthy controls were enrolled in this study. Serum levels of creatinine , calcium, phosphorus and alkaline phosphatase were measured and eGFR values correlated with the serum creatinine .RESULTS The mean values of creatinine (4.9 2.23 mgdl), calcium (9.8 0.456 mgdl) , phosphorus (4.19 0.404 mgdl) and alkaline phosphatase (94.01 15.10 UL) in the study group are significantly higher than the control group in which the mean levels are 0.89 0.102 mgdl, 10.17 0.37 mgdl, 4.02 0.16 mgdl and 25.16 4.65UL respectively. We have found that there is a significant difference in the above said parameters among patients in different stages of CKD (stage 3-5) indicating the progression of mineral bone disease with advancing stage of CKD.

 


Full Text:

PDF

References


Csaba P. Kovesdy , Vitalie Ureche, Jun L. Lu and Kamyar Kalantar-Zadeh: Outcome predictability of serum alkaline phosphatase in men with pre dialysis CKD: Nephro Dial Transplant (2010) 25: 3003-3011.

Amato AA, Santos GM.Neves F. Thyroid hormone action in chronic kidney disease. Current opinion in endocrinology, Diabetes and Obesity. 2008; 15:459-465.

Muthu MK. Prevention of chronic renal failure at the community level. Kidney Int Suppl.2003;83:S86-S89.

Tangri N, Stevens LA, Griffith J. A predictive model for progression of chronic kidney disease to kidney failure. JAMA,2011;305(15):1553-9.

KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis.2002.

KDIGO Clinical Practice Guidiline for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder. Kidney Int.2009

Amann K, Wolf B, Nichols C et al. Aortic changes in experimental renal failure hyperplasia or hypertrophy of smooth muscle cells? Hypertension. 1997;29:770-775

Sirgrist MK, Taal MW, Bungay P, Mclntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 adn 5 chronic kidney disease. Clin J Am Soc Nephrol.2007:1241-48

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-2218

Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time arying indicators o bone disease in maintanence hemodialysis patients. Kidney Int 2006; 70:771-780.

Kovesdy CP, Kalantar-Zadeh K. Bone and mineral kisorders in predialysis CKD. Int Urol Nephrol 2008; 40: 427-440.

Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease, J Am Soc Nephrol 2005; 16: 520-528.

Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pro-dialysis patients. Nephrol Dial Transplant 2007; 22:2909-2916.

Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int

; 73: 1296-1302.

O’Neill WC. Pyrophosphatase, alkaline phosphatase, and vascular calcification. Circ Res 2006; 99:e2.

Shantouf R, Kovesdy CP, Kim Y et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:1106-1114.

Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1805-1810.

Magnusson P, Sharp CA, Magnusson C, Riseli J, Davie MW, Larsson L, Effect of chronic renal failure on bone urnover and bone alkaone phosphatase isoforms. Kidney Int 2001; 60:257-265

Torres PU. Bone alkaline phosphatase isoforms in chronic renal failure. Kidney Int 2002; 61: 1178-1179

Regodpr DL, Kovesdy CP. Mehrotra R et al. Serum alkaline phosphatase predicts mortality among mainteneance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203.

Scialla JJ1, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M. Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol. 2013 Jan;24(1):125-35.

Kim, Chung W, Kim S.et al. Vitamin D, and kidney disease. Electrolyte Blood Press. 2011 Jun;9(1):1-6.

Lee at al. Impact of Kidney Bone Disease and Its Management on Survival of Patients on Dialysis. Journal of Renal Nutrition Volume 17, Issue 1, Pages 38–44, January 2007.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr M.G.R. Medical University